Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

20.56EUR
15 Dec 2017
Change (% chg)

€0.28 (+1.38%)
Prev Close
€20.28
Open
€20.22
Day's High
€20.56
Day's Low
€20.20
Volume
296,418
Avg. Vol
381,611
52-wk High
€20.72
52-wk Low
€10.09

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.58
Market Cap(Mil.): €1,536.26
Shares Outstanding(Mil.): 74.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Ablynx Reports Additional Clinically Important Benefits Of Caplacizumab

* ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP

Dec 12 2017

BRIEF-Ablynx 9-month revenues decrease to 44.7 million euros ​

* 9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​

Nov 16 2017

BRIEF-Ablynx announces full exercise of underwriters' option to purchase additional shares

* ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

Oct 27 2017

BRIEF-Ablynx prices $200 mln IPO in the United States

* Ablynx prices $200 million initial public offering in the United States

Oct 24 2017

BRIEF-Ablynx NV now sees IPO of up to 9.5 mln ordinary shares

* Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing

Oct 24 2017

BRIEF-Ablynx NV offers 9.2 million of its ordinary shares in global offering

* Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing

Oct 20 2017

BRIEF-Ablynx to offer and sell about $175 million of its ordinary shares

* ‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​

Oct 17 2017

BRIEF-Ablynx establishes subsidiary in USA

* ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 16 2017

BRIEF-Ablynx NV files for U.S. IPO of up to $150 mln

* Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​

Oct 02 2017

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

Oct 02 2017

Earnings vs. Estimates